M. Ducreux

Phase II, randomized, biomarker identification trial (MARK) for erlotinib in patients with advanced pancreatic carcinoma.

M. Ducreux, L. Kupčinskas, B. Klughammer, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Frequency, technical aspects, results, and indications of major hepatectomy after prolonged intra-arterial hepatic chemotherapy for initially unresectable hepatic tumors.

M. Ducreux, P. Rougier, D. Elias, 1995, Journal of the American College of Surgeons.

Interventional oncology for liver and lung metastases from colorectal cancer: The current state of the art.

T. de Baère, M. Ducreux, D. Elias, 2015, Diagnostic and interventional imaging.

Surgical treatment of hepatic and pulmonary metastases from colorectal cancers.

L. Spaggiari, M. Ducreux, D. Elias, 1998, The Annals of thoracic surgery.

The multidisciplinary management of gastro-oesophageal junction tumours: European Society of Digestive Oncology (ESDO): Expert discussion and report from the 16th ESMO World Congress on Gastrointestinal Cancer, Barcelona.

K. Haustermans, F. Lordick, M. Ducreux, 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

Prognostic factors in patients with liver metastases from colorectal carcinoma treated with discontinuous intra-arterial hepatic chemotherapy.

J. Pignon, M. Ducreux, P. Rougier, 1991, European journal of cancer.

Resection of liver metastases from a noncolorectal primary: indications and results based on 147 monocentric patients.

B. Plaud, S. Bonvalot, M. Ducreux, 1998, Journal of the American College of Surgeons.

The differential response to chemotherapy of ovarian metastases from colorectal carcinoma.

M. Ducreux, M. Pocard, D. Elias, 2008, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Liver, lung and peritoneal metastases in colorectal cancers: is the patient still curable? What should the radiologist know.

C. Caramella, P. Dartigues, D. Goéré, 2014, Diagnostic and interventional imaging.

Irinotecan is active in chemonaive patients with metastatic gastric cancer: a phase II multicentric trial

M. Ducreux, C. Köhne, N. Niederle, 2003, British Journal of Cancer.